These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 24495942)

  • 61. Multi-Targeted Tyrosine Kinase Inhibitor-Induced Hyperammonemic Encephalopathy: a Report of Two Cases Using Pazopanib, Sunitinib, and Regorafenib.
    Kongsuphon N; Soukavanitch M; Teeraaumpornpunt N; Konmun J; Ativitavas T; Ngamphaiboon N
    J Gastrointest Cancer; 2019 Sep; 50(3):601-603. PubMed ID: 29411249
    [No Abstract]   [Full Text] [Related]  

  • 62. Expert opinion on the metabolic complications of new anticancer therapies: Tyrosine kinase inhibitors.
    Buffier P; Bouillet B; Smati S; Archambeaud F; Cariou B; Verges B
    Ann Endocrinol (Paris); 2018 Oct; 79(5):574-582. PubMed ID: 30174137
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Sunitinib associated posterior reversible encephalopathy syndrome in a patient treated for GIST.
    Rifino N; Mantero V; Filizzolo MG; Basilico P; Scaccabarozzi C; Arnoffi J; Salmaggi A
    Acta Neurol Belg; 2020 Aug; 120(4):995-997. PubMed ID: 32372399
    [No Abstract]   [Full Text] [Related]  

  • 64. Alternative schedules or integration strategies to maximise treatment duration with sunitinib in patients with gastrointestinal stromal tumours.
    Saponara M; Lolli C; Nannini M; DI Scioscio V; Serra C; Mandrioli A; Pallotti MC; Biasco G; Pantaleo MA
    Oncol Lett; 2014 Oct; 8(4):1793-1799. PubMed ID: 25202412
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Endocrine side effects of broad-acting kinase inhibitors.
    Lodish MB; Stratakis CA
    Endocr Relat Cancer; 2010 Sep; 17(3):R233-44. PubMed ID: 20603395
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A patient's perspective on the side effects of tyrosine kinase inhibitors in the treatment of advanced and metastatic gastrointestinal stromal tumors.
    van de Wal D; Venkatesan S; Benson C; van der Graaf WTA; Johnson CD; Husson O; Sodergren SC
    Future Oncol; 2023 Feb; 19(4):299-314. PubMed ID: 37038981
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Health-Related Quality of Life and Side Effects in Gastrointestinal Stromal Tumor (GIST) Patients Treated with Tyrosine Kinase Inhibitors: A Systematic Review of the Literature.
    van de Wal D; Elie M; Le Cesne A; Fumagalli E; den Hollander D; Jones RL; Marquina G; Steeghs N; van der Graaf WTA; Husson O
    Cancers (Basel); 2022 Apr; 14(7):. PubMed ID: 35406604
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Targeted therapy for cancer: asking the right questions.
    Schilsky RL
    Oncology (Williston Park); 2012 Oct; 26(10):947-9. PubMed ID: 23176006
    [No Abstract]   [Full Text] [Related]  

  • 69. Improving harmonious precision.
    Kim JW; Marshall JL
    Oncology (Williston Park); 2012 Oct; 26(10):949, 954. PubMed ID: 23176007
    [No Abstract]   [Full Text] [Related]  

  • 70. Dermatological adverse drug reactions to tyrosine kinase inhibitors: a narrative review.
    Das A; Sil A; Khan IA; Bandyopadhyay D
    Clin Exp Dermatol; 2023 Jun; 48(6):599-608. PubMed ID: 36806485
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Sunitinib-Induced Acute Liver Failure.
    Aqsa A; Droubi S; Amarnath S; Al-Moussawi H; Abergel J
    Case Rep Gastroenterol; 2021; 15(1):17-21. PubMed ID: 33613158
    [TBL] [Abstract][Full Text] [Related]  

  • 72. THERAPY OF ENDOCRINE DISEASE: Endocrine-metabolic effects of treatment with multikinase inhibitors.
    Fallahi P; Ferrari SM; Elia G; Ragusa F; Paparo SR; Camastra S; Mazzi V; Miccoli M; Benvenga S; Antonelli A
    Eur J Endocrinol; 2021 Jan; 184(1):R29-R40. PubMed ID: 33112294
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A Rare Case of Sunitinib-Induced Exfoliative Esophagitis.
    Gayam S; Anumandla A
    ACG Case Rep J; 2016 Aug; 3(4):e155. PubMed ID: 27921054
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The side effects of imatinib.
    Uzer E; Unal A; Köker MY; Doğan SA
    Turk J Haematol; 2013 Sep; 30(3):341. PubMed ID: 24385822
    [No Abstract]   [Full Text] [Related]  

  • 75. Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.
    Caldemeyer L; Dugan M; Edwards J; Akard L
    Curr Hematol Malig Rep; 2016 Apr; 11(2):71-9. PubMed ID: 26922746
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Phagotest and Bursttest (Phagoburst), test kits for study of phagocyte functions].
    Hirt W; Nebe T; Birr C
    Wien Klin Wochenschr; 1994; 106(8):250-2. PubMed ID: 8023517
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Mechanism of fibronectin-mediated cell migration: dependence or independence of cell migration susceptibility on RGDS-directed receptor (integrin).
    Straus AH; Carter WG; Wayner EA; Hakomori S
    Exp Cell Res; 1989 Jul; 183(1):126-39. PubMed ID: 2544438
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Glassy carbon electrodes modified with graphitic carbon nitride nanosheets and CoNiO
    Kholafazadehastamal G; Erk N; Genc AA; Erbas Z; Soylak M
    Mikrochim Acta; 2024 Aug; 191(9):527. PubMed ID: 39120802
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A case-matched study of imatinib mesylate between different formulations on plasma trough concentration, adverse events, quality of life and outcomes in gastrointestinal stromal tumor patients.
    Zeng L; Cheng X; Li J; Zhang J; Wu X
    PLoS One; 2024; 19(5):e0303290. PubMed ID: 38743680
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Psychological Distress, Fatigue and Quality of Life in Patients with Gastrointestinal Stromal Tumors.
    Carbajal-López EB; Juárez-García DM; Sánchez-Jauregui TJ; Espinoza-Velazco A; Calderillo-Ruiz G; Salas-Benavides R
    Psychol Russ; 2022; 15(2):3-13. PubMed ID: 36699707
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.